Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0016382 (
flushing
)
6,387
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A column-switching liquid chromatographic method is described for the simultaneous determination of aspirin and
salicylic acid
in human plasma. Blood samples are taken into chilled tubes containing a fluoride anticoagulant, and the plasma is isolated by centrifugation. Following a simple acidification step, a 200 microL aliquot of the sample is injected directly onto the HPLC system. The C-18 extraction column is washed with acidified water for 2 min, after which time the compounds are removed by back-
flushing
directly onto the analytical column (C-8 Nucleosil, 5 microns, 250 mm x 4.6 mm). The flow rate through both columns is 1 mL/min, and the analytes are quantified by measurement of their UV absorbance at 225 nm. The mobile phase is a mixture of water-methanol-acetonitrile-orthophosphoric acid (650:200:150:1 v/v/v/v). The method is linear in the concentration ranges 0.10-5.00 micrograms/mL for aspirin and 0.25-15.00 micrograms/mL for
salicylic acid
. Both compounds have a limit of quantitation of 0.10 microgram/mL and a limit of detection of 0.04 microgram/mL. Extensive stability tests have been carried out, and validation studies reveal the method to be reproducible and repeatable. Excellent recoveries from plasma obviate the need for an internal standard. The procedure is easier to execute and requires less sample handling than methods currently described in the literature. It has been successfully applied to the investigation of the levels of aspirin and
salicylic acid
in a healthy, nonfasting volunteer following a 600 mg oral dose of aspirin.
...
PMID:Determination of aspirin and salicylic acid in human plasma by column-switching liquid chromatography using on-line solid-phase extraction. 945 Mar 67
Nicotinic acid (NA) is highly effective and widely used in the management of dyslipidaemia. For many patients, the side effect of
flushing
of the face and upper body leads to discontinuation.
Flushing
with NA is mediated by prostaglandins, and as acetyl
salicylic acid
(ASA, 'aspirin') is a highly effective inhibitor of prostaglandin synthesis, there is a rationale for its use to prevent or reduce the severity of NA-related
flushing
. This literature survey identified four studies specifically exploring the utility of ASA in preventing NA-related
flushing
in healthy volunteers. Twenty-three NA studies, where ASA was mandatory or optional within the protocol, and four studies, where background ASA therapy was reported in most participants, were also identified. Although the incidence of
flushing
in studies using ASA was often high, discontinuation rates due to
flushing
were low (mean 7.7%). This figure compares favourably with discontinuation rates with NA commonly reported in the literature (up to approximately 40%). There is good supportive evidence for the use of ASA in reducing the severity of NA-related
flushing
.
...
PMID:Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. 1680 57